TheranosticTrials.org

Clinical Trial · NCT07462507

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

Overview

Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.

Sponsor

Washington University School of Medicine

Phase

Phase 2

Contacts

Tammie L.S. Benzinger, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

Tammie L.S. Benzinger, M.D., Ph.D. (CONTACT)

benzingert@wustl.edu

314-362-6110

Jayashree Rajamanickam (CONTACT)

jayashree.r@wustl.edu

314-273-6140

ClinicalTrials.gov

NCT07462507

Drug / Compound

CS1P1

Isotope(s):
Target(s):
  • S1P1
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Has a clinical, radiographic, or pathological diagnosis of primary or secondary CNS malignancy that has not been treated with radiotherapy
  • Capable of providing written informed consent OR having a legally authorized representative (LAR) to provide informed consent for volunteering to undergo research procedure
  • * Male or female, any race
  • Age ≥ 18 years

Exclusion

  • * Hypersensitivity to \[C-11\]-CS1P1 or any of its excipients
  • Women who are currently pregnant or breastfeeding
  • Contraindications to PET, CT or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate
  • Severe claustrophobia that would require general anesthesia
  • Prior cranial radiotherapy